Abbott has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volttm PFA System ...

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt PFA SystemThe 12-month results of the ...

Medtronic plc , a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Afferatm family of ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

Researchers at UC San Diego Health have developed an AI-powered, non-invasive mapping system to accurately locate arrhythmia ...

Led by Farapulse founder Steven Mickelsen, Field has developed a pulsed field ablation device to tackle the dangerous heart ...

Dr. Paul Dorian, MD, CM, MSc., Cardiologist, discusses atrial fibrillation treatment options. Trump had a ‘test case’ for ...

The biomedical market’s latest technology for treating irregular heartbeats has made its way to the Flathead Valley, bringing ...